News

Linerixibat is the first drug approved in the United States to treat cholestatic pruritis in adults living with PBC.

New research shows that while risk of death in PBC is higher regardless of cirrhosis status, early-stage diagnosis has a more favorable outlook.

The one-year results of a Phase 2a trial showed improvements across several measures associated with liver health and PBC progression.

The registry is helping improve PBC care by connecting PBC patients in Ireland with researchers and patient groups around the world.

Patients with primary biliary cholangitis and autoimmune hepatitis showed consistent changes in mouth bacteria compared with healthy people.

Fenofibrate may offer sustained benefits for individuals living with PBC who do not fully respond to first-line therapy ursodeoxycholic acid.

While PBC is traditionally linked to symptoms like fatigue and itching, up to half of those affected develop osteoporosis.

A recent study found that recompensation can be a useful clinical endpoint in patients with PBC and decompensated cirrhosis.

Patients with PBC should undergo endoscopic assessments to rule out hidden diseases.

New research explores how type 2 diabetes affects fatty liver, scarring and outcomes in people living with primary biliary cholangitis.